<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448669</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCHHSTP-4940</org_study_id>
    <secondary_id>BOTUSA MB06</secondary_id>
    <nct_id>NCT00448669</nct_id>
  </id_info>
  <brief_title>Botswana TDF/FTC Oral HIV Prophylaxis Trial</brief_title>
  <acronym>TDF2</acronym>
  <official_title>Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Botswana Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tested whether taking a pill of tenofovir and emtricitabine (two antiretroviral
      medicines) was safe for sexually-active young adults in Botswana without HIV infection and
      whether it reduced their risk of getting an HIV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twelve hundred and nineteen healthy, sexually active women and men, 18-39 years old, without
      HIV infection were enrolled in Francistown and Gaborone, Botswana. They were provided with
      free male and female condoms, repeated individualized risk-reduction counseling, diagnosis
      and treatment of sexually transmitted diseases, and women will be provided with a choice of
      effective family planning methods. In addition, volunteers were randomized to receive either
      Tenofovir and emtricitabine (in a single pill) or a placebo pill to take once a day.
      Volunteers were seen monthly for at least 12 months to monitor for side effects and
      toxicities and to test their HIV status. Persons who become HIV infected during the trial
      received ongoing supportive counseling, CD4 and viral load monitoring, education about HIV
      infection/disease, and access to HIV care including free antiretrovirals when clinically
      indicated. Volunteer safety was monitored by a local ethics committee, Centers for Disease
      Control Institutional Review Board (CDC IRB) and an independent data safety and monitoring
      board
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Drug Reactions in the Tenofovir/Emtricitabine and Placebo Arms</measure>
    <time_frame>Monthly, for up to 3 years</time_frame>
    <description>Study visits were scheduled every 30 days until completion of the study, and participants were instructed to return to the clinic for evaluation in the event of an illness. Participants reported any adverse effects at monthly visits and interim visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV Incidence in the Tenofovir/Emtricitabine and Placebo Arms</measure>
    <time_frame>Monthly, for up to 3 years</time_frame>
    <description>Study visits were scheduled every 30 days until completion of the study and during monthly study visits, we performed testing for HIV infection. At completion of the study, we tested all participants for HIV infection, using an enzyme-linked immunosorbent assay (ELISA).The primary efficacy end point was the difference in the rates of HIV infection between participants assigned to receive TDF-FTC and those assigned to receive placebo. The initial efficacy analysis included all study participants who were randomly assigned to receive a study medication (intention-to-treat cohort).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Condom Use During Study: Number of Participants With &gt;=1 Condomless Sex Acts</measure>
    <time_frame>12 months</time_frame>
    <description>We assessed condom use of the enrolled participants by face-to-face interviews (at baseline and monthly thereafter) and provided a comprehensive package of HIV prevention services, including individualized counseling on risk reduction, free male and female condoms, and screening for sexually transmitted infections followed, if applicable, by partner notification and treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Adherence to Study Medication</measure>
    <time_frame>36 months</time_frame>
    <description>The rates of adherence to study medication by treatment arm was assessed over the entire course of the study. This comparison was done by assessing the percentage of pills taken by participants within each study arm. The difference between the 2 arms was compared with a Fisher' exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral (ARV) Resistance Patterns in Seroconverters</measure>
    <time_frame>At time HIV infection diagnosed,1 month post-time of HIV infection diagnosis, and 6 months post-time of HIV infection diagnosis</time_frame>
    <description>Participants who seroconverted had blood samples taken at the time of infection and at one month and six months post seroconversion to detect any HIV resistance mutations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Evaluation After HIV Seroconversion</measure>
    <time_frame>1-year post seroconversion</time_frame>
    <description>Study medication was stopped when HIV infected was diagnosed. Seroconvertors were referred for clinical care and followed an additional year with scheduled quarterly CD4+ cell count assessments. A model-estimated geometric mean of the CD4+ cell counts by each treatment group was evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1219</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>TDF-FTC,condoms,adh/risk counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible participants were randomized to oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet. The ratio of randomization was 1:1. Participants randomized to the active arm received male and female condoms, risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo,condoms,adh/risk counseling</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible participants were randomized to the placebo arm and received placebo oral tablets that were visually identical to the TDF-FTC tablet and taken once daily. The placebo tablets contained no active ingredients. The ratio of randomization was 1:1. Participants randomized to the placebo arm received male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg</intervention_name>
    <arm_group_label>TDF-FTC,condoms,adh/risk counseling</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <arm_group_label>Placebo,condoms,adh/risk counseling</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  citizen of Botswana 18-39 years old

          -  sexually active

          -  HIV uninfected

          -  Hepatitis B and C uninfected

          -  Calculated creatinine clearance &gt;= 60 mL/min

          -  hemoglobin &gt;= 8 gm/dL

          -  ALT and AST &lt;= 2x ULN

          -  total bilirubin &lt;= 1.5 mg/dL

          -  total serum amylase &lt;= 1.5x ULN

          -  Serum phosphorus &gt;= 2.2 mg/dL

          -  willing to use hormonal contraception (females)

          -  living within 1 hours travel of study clinic

          -  pass comprehension test

          -  willing and able to give informed consent

        Exclusion Criteria:

          -  18-20 without parent/guardian consent

          -  history of significant renal or bone disease

          -  any chronic illness requiring ongoing prescription medication

          -  pregnant or breastfeeding

          -  planning to move away from site in the next year

          -  participating in another HIV prevention or vaccine safety trial

          -  any other clinical condition or prior therapy that, in the opinion of the study
             physician, would make the volunteer unsuitable for the study or unable to comply with
             the dosing requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Thigpen, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health (NIH)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynn Paxton, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centers for Disease Control and Prevention</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30333</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BOTUSA HIV Prevention Research Unit</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Toledo L, McLellan-Lemal E, Henderson FL, Kebaabetswe PM. Knowledge, Attitudes, and Experiences of HIV Pre-Exposure Prophylaxis (PrEP) Trial Participants in Botswana. World J AIDS. 2015 Mar;5(2):10-20. Epub 2015 Feb 12.</citation>
    <PMID>26767149</PMID>
  </reference>
  <reference>
    <citation>Kasonde M, Niska RW, Rose C, Henderson FL, Segolodi TM, Turner K, Smith DK, Thigpen MC, Paxton LA. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS One. 2014 Mar 13;9(3):e90111. doi: 10.1371/journal.pone.0090111. eCollection 2014.</citation>
    <PMID>24625530</PMID>
  </reference>
  <reference>
    <citation>Chirwa LI, Johnson JA, Niska RW, Segolodi TM, Henderson FL, Rose CE, Li JF, Thigpen MC, Matlhaba O, Paxton LA, Brooks JT. CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis. AIDS. 2014 Jan 14;28(2):223-6. doi: 10.1097/QAD.0000000000000102.</citation>
    <PMID>24361682</PMID>
  </reference>
  <reference>
    <citation>Kebaabetswe PM, Stirratt MJ, McLellan-Lemal E, Henderson FL, Gray SC, Rose CE, Williams T, Paxton LA. Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010. AIDS Behav. 2015 May;19(5):758-69. doi: 10.1007/s10461-014-0891-z.</citation>
    <PMID>25186785</PMID>
  </reference>
  <reference>
    <citation>Segolodi TM, Henderson FL, Rose CE, Turner KT, Zeh C, Fonjungo PN, Niska R, Hart C, Paxton LA. Normal laboratory reference intervals among healthy adults screened for a HIV pre-exposure prophylaxis clinical trial in Botswana. PLoS One. 2014 Apr 8;9(4):e93034. doi: 10.1371/journal.pone.0093034. eCollection 2014.</citation>
    <PMID>24714095</PMID>
  </reference>
  <results_reference>
    <citation>Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012 Aug 2;367(5):423-34. doi: 10.1056/NEJMoa1110711. Epub 2012 Jul 11.</citation>
    <PMID>22784038</PMID>
  </results_reference>
  <results_reference>
    <citation>Gust DA, Soud F, Hardnett FP, Malotte CK, Rose C, Kebaabetswe P, Makgekgenene L, Henderson F, Paxton L, Segolodi T, Kilmarx PH. Evaluation of Sexual Risk Behavior Among Study Participants in the TDF2 PrEP Study Among Heterosexual Adults in Botswana. J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):556-563.</citation>
    <PMID>27509251</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>March 16, 2007</study_first_submitted>
  <study_first_submitted_qc>March 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2007</study_first_posted>
  <results_first_submitted>May 22, 2015</results_first_submitted>
  <results_first_submitted_qc>January 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2020</results_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV incidence</keyword>
  <keyword>HIV prevention</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>Emtricitabine</keyword>
  <keyword>Botswana</keyword>
  <keyword>HIV seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data sharing will be governed by prevailing CDC data sharing policies.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TDF-FTC, Condoms, Risk Counseling</title>
          <description>Participants randomized to the active arm received daily oral TDF-FTC along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg: Daily oral single dose pill containing 300 mg TDF and 200 mg FTC.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Condoms, Risk Counseling</title>
          <description>Participants randomized to the placebo arm received a daily oral placebo tablet along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
TDF-FTC placebo: Placebo comparator for TDF-FTC</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="611"/>
                <participants group_id="P2" count="608"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="393"/>
                <participants group_id="P2" count="410"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocated</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Were withdrawn by investigator</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Had other reasons</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>HIV-infected at enrollment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never started drug</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 1219 underwent randomization. Of the 611 assigned to TDF-FTC: 9 did not start TDF-FTC and 1 was HIV-infected at enrollment. Of the 608 assigned to placebo: 7 did not start placebo and 2 were HIV-infected at enrollment.</population>
      <group_list>
        <group group_id="B1">
          <title>TDF-FTC, Condoms, Risk Counseling</title>
          <description>Participants randomized to the active arm received daily oral TDF-FTC along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg: Daily oral single dose pill containing 300 mg TDF and 200 mg FTC.</description>
        </group>
        <group group_id="B2">
          <title>Placebo, Condoms, Risk Counseling</title>
          <description>Participants randomized to the placebo arm received a daily oral placebo tablet along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
TDF-FTC placebo: Placebo comparator for TDF-FTC</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="611"/>
            <count group_id="B2" value="608"/>
            <count group_id="B3" value="1219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="611"/>
                    <measurement group_id="B2" value="608"/>
                    <measurement group_id="B3" value="1219"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                    <measurement group_id="B2" value="277"/>
                    <measurement group_id="B3" value="557"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="331"/>
                    <measurement group_id="B2" value="331"/>
                    <measurement group_id="B3" value="662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Botswana</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="611"/>
                    <measurement group_id="B2" value="608"/>
                    <measurement group_id="B3" value="1219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Drug Reactions in the Tenofovir/Emtricitabine and Placebo Arms</title>
        <description>Study visits were scheduled every 30 days until completion of the study, and participants were instructed to return to the clinic for evaluation in the event of an illness. Participants reported any adverse effects at monthly visits and interim visits.</description>
        <time_frame>Monthly, for up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TDF-FTC, Condoms, Risk Counseling</title>
            <description>Participants randomized to the active arm received daily oral TDF-FTC along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg: Daily oral single dose pill containing 300 mg TDF and 200 mg FTC.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Condoms, Risk Counseling</title>
            <description>Participants randomized to the placebo arm received a daily oral placebo tablet along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
TDF-FTC placebo: Placebo comparator for TDF-FTC</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Drug Reactions in the Tenofovir/Emtricitabine and Placebo Arms</title>
          <description>Study visits were scheduled every 30 days until completion of the study, and participants were instructed to return to the clinic for evaluation in the event of an illness. Participants reported any adverse effects at monthly visits and interim visits.</description>
          <units>percentage of participants with AE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="611"/>
                <count group_id="O2" value="608"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2"/>
                    <measurement group_id="O2" value="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Safety analyses were performed in the intention-to-treat cohort. Primary safety end points included the frequency of adverse clinical or laboratory events.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Regression, Cox</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HIV Incidence in the Tenofovir/Emtricitabine and Placebo Arms</title>
        <description>Study visits were scheduled every 30 days until completion of the study and during monthly study visits, we performed testing for HIV infection. At completion of the study, we tested all participants for HIV infection, using an enzyme-linked immunosorbent assay (ELISA).The primary efficacy end point was the difference in the rates of HIV infection between participants assigned to receive TDF-FTC and those assigned to receive placebo. The initial efficacy analysis included all study participants who were randomly assigned to receive a study medication (intention-to-treat cohort).</description>
        <time_frame>Monthly, for up to 3 years</time_frame>
        <population>Of the 1219, 3 were excluded from analysis because HIV-infected at the time of enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF-FTC, Condoms, Risk Counseling</title>
            <description>Participants randomized to the active arm received daily oral TDF-FTC along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg: Daily oral single dose pill containing 300 mg TDF and 200 mg FTC.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Condoms, Risk Counseling</title>
            <description>Participants randomized to the placebo arm received a daily oral placebo tablet along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
TDF-FTC placebo: Placebo comparator for TDF-FTC</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Incidence in the Tenofovir/Emtricitabine and Placebo Arms</title>
          <description>Study visits were scheduled every 30 days until completion of the study and during monthly study visits, we performed testing for HIV infection. At completion of the study, we tested all participants for HIV infection, using an enzyme-linked immunosorbent assay (ELISA).The primary efficacy end point was the difference in the rates of HIV infection between participants assigned to receive TDF-FTC and those assigned to receive placebo. The initial efficacy analysis included all study participants who were randomly assigned to receive a study medication (intention-to-treat cohort).</description>
          <population>Of the 1219, 3 were excluded from analysis because HIV-infected at the time of enrollment.</population>
          <units>infections/100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="610"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy end point was the difference in the rates of HIV infection between participants assigned to receive TDF–FTC and those assigned to receive placebo. The primary hypothesis was that TDF–FTC, as compared with placebo, would reduce the rate of HIV infection by at least 65%, with a predefined lower boundary for the 95% confidence interval of 10%.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Regression, Cox</method>
            <param_type>Efficacy</param_type>
            <param_value>62.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.5</ci_lower_limit>
            <ci_upper_limit>83.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Condom Use During Study: Number of Participants With &gt;=1 Condomless Sex Acts</title>
        <description>We assessed condom use of the enrolled participants by face-to-face interviews (at baseline and monthly thereafter) and provided a comprehensive package of HIV prevention services, including individualized counseling on risk reduction, free male and female condoms, and screening for sexually transmitted infections followed, if applicable, by partner notification and treatment.</description>
        <time_frame>12 months</time_frame>
        <population>Of 1219, 19 excluded (3 HIV-infected at enrollment, 16 never started drug). Of the 1200, 24 reported no sex during study. Remaining total 1176 with &gt;=1 sex act included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF-FTC, Condoms, Risk Counseling</title>
            <description>Participants randomized to the active arm received daily oral TDF-FTC along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg: Daily oral single dose pill containing 300 mg TDF and 200 mg FTC.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Condoms, Risk Counseling</title>
            <description>Participants randomized to the placebo arm received a daily oral placebo tablet along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
TDF-FTC placebo: Placebo comparator for TDF-FTC</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Condom Use During Study: Number of Participants With &gt;=1 Condomless Sex Acts</title>
          <description>We assessed condom use of the enrolled participants by face-to-face interviews (at baseline and monthly thereafter) and provided a comprehensive package of HIV prevention services, including individualized counseling on risk reduction, free male and female condoms, and screening for sexually transmitted infections followed, if applicable, by partner notification and treatment.</description>
          <population>Of 1219, 19 excluded (3 HIV-infected at enrollment, 16 never started drug). Of the 1200, 24 reported no sex during study. Remaining total 1176 with &gt;=1 sex act included in analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="611"/>
                <count group_id="O2" value="608"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="506"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="449"/>
                    <count group_id="O2" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="414"/>
                    <count group_id="O2" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="358"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="357"/>
                    <count group_id="O2" value="326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="339"/>
                    <count group_id="O2" value="326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="323"/>
                    <count group_id="O2" value="341"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="266"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="243"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A logistic regression was used to estimate the odds of reporting zero condomless sex acts. The longitudinal dependent variable (number of condomless sex acts) was defined as:
Number of condomless vaginal sexual acts with both casual and main partners among those who reported having had at least one sexual partner in the previous 30 days.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Regression, Logistic</method>
            <method_desc>In this univariate model with the analysis of number of condomless sex acts, our model estimates the odds of reporting no condomless sex acts.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Adherence to Study Medication</title>
        <description>The rates of adherence to study medication by treatment arm was assessed over the entire course of the study. This comparison was done by assessing the percentage of pills taken by participants within each study arm. The difference between the 2 arms was compared with a Fisher' exact test.</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TDF-FTC, Condoms, Risk Counseling</title>
            <description>Participants randomized to the active arm received daily oral TDF-FTC along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg: Daily oral single dose pill containing 300 mg TDF and 200 mg FTC.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Condoms, Risk Counseling</title>
            <description>Participants randomized to the placebo arm received a daily oral placebo tablet along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
TDF-FTC placebo: Placebo comparator for TDF-FTC</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Adherence to Study Medication</title>
          <description>The rates of adherence to study medication by treatment arm was assessed over the entire course of the study. This comparison was done by assessing the percentage of pills taken by participants within each study arm. The difference between the 2 arms was compared with a Fisher' exact test.</description>
          <units>Percentage of pills taken</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="611"/>
                <count group_id="O2" value="608"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5" spread="0.136"/>
                    <measurement group_id="O2" value="93.6" spread="0.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fisher’s Exact Test was performed to test for differences between the treatment groups in terms of adherence based on pill count.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antiretroviral (ARV) Resistance Patterns in Seroconverters</title>
        <description>Participants who seroconverted had blood samples taken at the time of infection and at one month and six months post seroconversion to detect any HIV resistance mutations.</description>
        <time_frame>At time HIV infection diagnosed,1 month post-time of HIV infection diagnosis, and 6 months post-time of HIV infection diagnosis</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TDF-FTC, Condoms, Risk Counseling</title>
            <description>Participants randomized to the active arm received daily oral TDF-FTC along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg: Daily oral single dose pill containing 300 mg TDF and 200 mg FTC.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Condoms, Risk Counseling</title>
            <description>Participants randomized to the placebo arm received a daily oral placebo tablet along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
TDF-FTC placebo: Placebo comparator for TDF-FTC</description>
          </group>
        </group_list>
        <measure>
          <title>Antiretroviral (ARV) Resistance Patterns in Seroconverters</title>
          <description>Participants who seroconverted had blood samples taken at the time of infection and at one month and six months post seroconversion to detect any HIV resistance mutations.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Evaluation After HIV Seroconversion</title>
        <description>Study medication was stopped when HIV infected was diagnosed. Seroconvertors were referred for clinical care and followed an additional year with scheduled quarterly CD4+ cell count assessments. A model-estimated geometric mean of the CD4+ cell counts by each treatment group was evaluated.</description>
        <time_frame>1-year post seroconversion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TDF-FTC Seroconvertor Group</title>
            <description>Participants who were assigned to receive TDF-FTC and seroconverted.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Seroconvertor Group</title>
            <description>Participants who were assigned to receive the placebo and seroconverted.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Evaluation After HIV Seroconversion</title>
          <description>Study medication was stopped when HIV infected was diagnosed. Seroconvertors were referred for clinical care and followed an additional year with scheduled quarterly CD4+ cell count assessments. A model-estimated geometric mean of the CD4+ cell counts by each treatment group was evaluated.</description>
          <units>cells/microliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500" lower_limit="378" upper_limit="661"/>
                    <measurement group_id="O2" value="466" lower_limit="396" upper_limit="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected throughout the course of the study until study completion, i.e. up to 3 years.</time_frame>
      <desc>Adverse events were graded according to the National Institutes of Health Division of AIDS (DAIDS) Table for Grading Severity of Adult and Pediatric Adverse Events (December 2004).</desc>
      <group_list>
        <group group_id="E1">
          <title>TDF-FTC, Condoms, Risk Counseling</title>
          <description>Participants randomized to the active arm received daily oral TDF-FTC along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg: Daily oral single dose pill containing 300 mg TDF and 200 mg FTC.</description>
        </group>
        <group group_id="E2">
          <title>Placebo, Condoms, Risk Counseling</title>
          <description>Participants randomized to the placebo arm received a daily oral placebo tablet along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
TDF-FTC placebo: Placebo comparator for TDF-FTC</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD9-CM</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperamylasemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="611"/>
                <counts group_id="E2" events="18" subjects_affected="9" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperchloremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tonsillitis, acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Injury, non-fatal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="611"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>ICD9-CM</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="557" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="536" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Phosphate</sub_title>
                <counts group_id="E1" events="198" subjects_affected="122" subjects_at_risk="611"/>
                <counts group_id="E2" events="221" subjects_affected="138" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Bilirubin, total</sub_title>
                <counts group_id="E1" events="70" subjects_affected="41" subjects_at_risk="611"/>
                <counts group_id="E2" events="73" subjects_affected="39" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Sodium</sub_title>
                <counts group_id="E1" events="172" subjects_affected="126" subjects_at_risk="611"/>
                <counts group_id="E2" events="148" subjects_affected="113" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Potassium</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="611"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Bicarbonate</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="611"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Chloride</sub_title>
                <counts group_id="E1" events="30" subjects_affected="25" subjects_at_risk="611"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="34" subjects_affected="28" subjects_at_risk="611"/>
                <counts group_id="E2" events="44" subjects_affected="39" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="611"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="611"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="611"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Ear</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Polyphagia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="35" subjects_at_risk="611"/>
                <counts group_id="E2" events="33" subjects_affected="30" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjuctivitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="611"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Painful Eyes</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="611"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="611"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="33" subjects_affected="29" subjects_at_risk="611"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="93" subjects_affected="76" subjects_at_risk="611"/>
                <counts group_id="E2" events="76" subjects_affected="65" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="67" subjects_affected="56" subjects_at_risk="611"/>
                <counts group_id="E2" events="63" subjects_affected="58" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="611"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="132" subjects_affected="113" subjects_at_risk="611"/>
                <counts group_id="E2" events="48" subjects_affected="43" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pain, Abdominal</sub_title>
                <counts group_id="E1" events="214" subjects_affected="154" subjects_at_risk="611"/>
                <counts group_id="E2" events="217" subjects_affected="156" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="87" subjects_affected="69" subjects_at_risk="611"/>
                <counts group_id="E2" events="47" subjects_affected="43" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Amylase, Serum</sub_title>
                <counts group_id="E1" events="986" subjects_affected="306" subjects_at_risk="611"/>
                <counts group_id="E2" events="999" subjects_affected="293" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>AST/SGOT</sub_title>
                <counts group_id="E1" events="43" subjects_affected="36" subjects_at_risk="611"/>
                <counts group_id="E2" events="42" subjects_affected="38" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>ALT/SGPT</sub_title>
                <counts group_id="E1" events="47" subjects_affected="37" subjects_at_risk="611"/>
                <counts group_id="E2" events="66" subjects_affected="43" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Bilirubin, direct</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="611"/>
                <counts group_id="E2" events="25" subjects_affected="17" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy, unspecified</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="611"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="611"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="55" subjects_affected="53" subjects_at_risk="611"/>
                <counts group_id="E2" events="48" subjects_affected="45" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="611"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Generalized Pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="611"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="384" subjects_affected="225" subjects_at_risk="611"/>
                <counts group_id="E2" events="410" subjects_affected="225" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Oral Disease, Gingiva</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="611"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Oral Disease, Teeth</sub_title>
                <counts group_id="E1" events="43" subjects_affected="33" subjects_at_risk="611"/>
                <counts group_id="E2" events="51" subjects_affected="40" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pharyngitis, Acute</sub_title>
                <counts group_id="E1" events="45" subjects_affected="39" subjects_at_risk="611"/>
                <counts group_id="E2" events="38" subjects_affected="37" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="611"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Tonsilitis, Acute</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="611"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="385" subjects_affected="231" subjects_at_risk="611"/>
                <counts group_id="E2" events="439" subjects_affected="241" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bite</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="611"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Injury, Nonfatal</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="611"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="611"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pain, Acute Musculoskeletal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="611"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" events="72" subjects_affected="57" subjects_at_risk="611"/>
                <counts group_id="E2" events="89" subjects_affected="67" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pain, Joint</sub_title>
                <counts group_id="E1" events="34" subjects_affected="28" subjects_at_risk="611"/>
                <counts group_id="E2" events="27" subjects_affected="23" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pain, Limb</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="611"/>
                <counts group_id="E2" events="31" subjects_affected="28" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="109" subjects_affected="92" subjects_at_risk="611"/>
                <counts group_id="E2" events="80" subjects_affected="65" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="611"/>
                <counts group_id="E2" events="29" subjects_affected="24" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="611"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Blood Urea Nitrogen</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Menses</sub_title>
                <counts group_id="E1" events="68" subjects_affected="54" subjects_at_risk="611"/>
                <counts group_id="E2" events="79" subjects_affected="64" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="611"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Breast Abnormalities</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="611"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Chlamydia</sub_title>
                <counts group_id="E1" events="85" subjects_affected="76" subjects_at_risk="611"/>
                <counts group_id="E2" events="83" subjects_affected="75" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="47" subjects_affected="32" subjects_at_risk="611"/>
                <counts group_id="E2" events="46" subjects_affected="34" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Genital Herpes</sub_title>
                <counts group_id="E1" events="43" subjects_affected="28" subjects_at_risk="611"/>
                <counts group_id="E2" events="46" subjects_affected="35" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Gonorrhea</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="611"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Leukorrhea</sub_title>
                <counts group_id="E1" events="39" subjects_affected="30" subjects_at_risk="611"/>
                <counts group_id="E2" events="64" subjects_affected="53" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pain, Genital</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="611"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pelvic Inflammatory Disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="611"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pruritus, Genital</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="611"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Sore Ulcer, Genital</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="611"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="611"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Urethral Discharge</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Vaginal Candidiasis</sub_title>
                <counts group_id="E1" events="42" subjects_affected="38" subjects_at_risk="611"/>
                <counts group_id="E2" events="37" subjects_affected="28" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="36" subjects_affected="31" subjects_at_risk="611"/>
                <counts group_id="E2" events="44" subjects_affected="39" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="611"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="611"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="611"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="611"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="611"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Dermatomycosis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="611"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Dermatophytosis</sub_title>
                <counts group_id="E1" events="35" subjects_affected="34" subjects_at_risk="611"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Disturbance of Skin Sensation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="611"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Edema, limb</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pruritus, Unspecified</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="611"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Rash, Unspecified</sub_title>
                <counts group_id="E1" events="44" subjects_affected="39" subjects_at_risk="611"/>
                <counts group_id="E2" events="48" subjects_affected="42" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Sore Ulcer, Oral Cavity</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="611"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="37" subjects_affected="33" subjects_at_risk="611"/>
                <counts group_id="E2" events="40" subjects_affected="34" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The rates of study completion were lower than predicted because more participants withdrew from the study, mostly due to relocation or conflicting obligations.Findings may not be generalizable to other populations.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Michael Thigpen</name_or_title>
      <organization>National Institutes of Health</organization>
      <phone>1-240-669-2877</phone>
      <email>michael.thigpen@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

